David Westenberg
Stock Analyst at Piper Sandler
(4.47)
# 279
Out of 5,170 analysts
197
Total ratings
53.57%
Success rate
20.12%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WGS GeneDx Holdings | Maintains: Overweight | $160 → $130 | $73.00 | +78.08% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $130 | $89.08 | +45.94% | 11 | Feb 24, 2026 | |
| NEO NeoGenomics | Maintains: Overweight | $12 → $13 | $8.18 | +58.92% | 11 | Feb 24, 2026 | |
| LH Labcorp Holdings | Maintains: Neutral | $270 → $300 | $264.09 | +13.60% | 5 | Feb 24, 2026 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $775 → $750 | $579.85 | +29.34% | 12 | Feb 9, 2026 | |
| ILMN Illumina | Maintains: Overweight | $195 → $170 | $126.59 | +34.29% | 17 | Feb 9, 2026 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $24 → $30 | $25.12 | +19.43% | 11 | Jan 22, 2026 | |
| ZTS Zoetis | Downgrades: Neutral | $190 → $135 | $115.99 | +16.39% | 16 | Jan 22, 2026 | |
| NEOG Neogen | Reiterates: Neutral | $6.5 → $10 | $8.70 | +14.94% | 14 | Jan 12, 2026 | |
| BLLN BillionToOne | Initiates: Overweight | $150 | $74.00 | +102.70% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $19 | $18.38 | +3.37% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $80 | $48.74 | +64.14% | 6 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $2 | $1.40 | +42.86% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $230 | $202.73 | +13.45% | 17 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $30 | $15.56 | +92.80% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $80 | $103.92 | -23.02% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7.5 | $4.51 | +66.30% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $200 | $194.16 | +3.01% | 8 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $13.50 | +48.15% | 15 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $16.57 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $25.51 | - | 1 | Nov 21, 2017 |
GeneDx Holdings
Feb 24, 2026
Maintains: Overweight
Price Target: $160 → $130
Current: $73.00
Upside: +78.08%
Guardant Health
Feb 24, 2026
Maintains: Overweight
Price Target: $120 → $130
Current: $89.08
Upside: +45.94%
NeoGenomics
Feb 24, 2026
Maintains: Overweight
Price Target: $12 → $13
Current: $8.18
Upside: +58.92%
Labcorp Holdings
Feb 24, 2026
Maintains: Neutral
Price Target: $270 → $300
Current: $264.09
Upside: +13.60%
IDEXX Laboratories
Feb 9, 2026
Maintains: Neutral
Price Target: $775 → $750
Current: $579.85
Upside: +29.34%
Illumina
Feb 9, 2026
Maintains: Overweight
Price Target: $195 → $170
Current: $126.59
Upside: +34.29%
Elanco Animal Health
Jan 22, 2026
Upgrades: Overweight
Price Target: $24 → $30
Current: $25.12
Upside: +19.43%
Zoetis
Jan 22, 2026
Downgrades: Neutral
Price Target: $190 → $135
Current: $115.99
Upside: +16.39%
Neogen
Jan 12, 2026
Reiterates: Neutral
Price Target: $6.5 → $10
Current: $8.70
Upside: +14.94%
BillionToOne
Dec 1, 2025
Initiates: Overweight
Price Target: $150
Current: $74.00
Upside: +102.70%
Nov 11, 2025
Maintains: Neutral
Price Target: $15 → $19
Current: $18.38
Upside: +3.37%
Nov 11, 2025
Maintains: Neutral
Price Target: $105 → $80
Current: $48.74
Upside: +64.14%
Nov 11, 2025
Maintains: Neutral
Price Target: $1.5 → $2
Current: $1.40
Upside: +42.86%
Nov 11, 2025
Maintains: Overweight
Price Target: $220 → $230
Current: $202.73
Upside: +13.45%
Nov 11, 2025
Maintains: Neutral
Price Target: $21 → $30
Current: $15.56
Upside: +92.80%
Nov 11, 2025
Maintains: Overweight
Price Target: $70 → $80
Current: $103.92
Upside: -23.02%
Nov 11, 2025
Maintains: Overweight
Price Target: $8 → $7.5
Current: $4.51
Upside: +66.30%
Oct 27, 2025
Maintains: Neutral
Price Target: $190 → $200
Current: $194.16
Upside: +3.01%
Oct 15, 2025
Maintains: Overweight
Price Target: $15 → $20
Current: $13.50
Upside: +48.15%
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $16.57
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $25.51
Upside: -